1-[3-(5-Methoxy-3,4-dihydro-naphthalen-1-yl)-propyl]-4-pyridin-2-yl-piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[3-(5-Methoxy-3,4-dihydro-naphthalen-1-yl)-propyl]-4-pyridin-2-yl-piperazine
• 英文别名: 1-[3-(5-methoxy-3,4-dihydronaphthalen-1-yl)propyl]-4-pyridin-2-ylpiperazine
• 化学式: C₂₃H₂₉N₃O
• 分子量: 363.5
• InChiKey: BNFNIRJQEHBDDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  28.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] RADIOLABELED COMPOUNDS AND METHODS THEREOF<br/>[FR] COMPOSÉS RADIOMARQUÉS ET LEURS PROCÉDÉS
  申请人：GE HEALTHCARE LTD

  公开号：WO2011150183A1

  公开（公告）日：2011-12-01

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射诊断化合物，制备这些化合物的方法，以及将其用作HA血清素5-HT1A受体的成像剂，用于PET或SPECT，更好地使用PET的方法。还披露了包含放射标记化合物的成像有效量的组合物。本发明还涉及非放射标记化合物，制备这些化合物的方法，以及将其用于治疗各种神经学和/或精神疾病的方法。
• RADIOLABELED COMPOUNDS AND METHODS THEREOF
  申请人：Newington Ian Martin

  公开号：US20130064770A1

  公开（公告）日：2013-03-14

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射性诊断化合物、制备这些化合物的方法以及将其用作成像剂的方法，优选地用于PET或SPECT，特别是HA 5-HT1A受体，其中包括成像有效量的放射性标记化合物的组合物。本发明还涉及非放射性标记化合物、制备这些化合物的方法以及将其用于治疗各种神经和/或精神障碍的方法。
• N(HETERO)-ARYL-N(HETERO)-TETRALIN-ALKYL-PIPERAZINE HAVING SEROTONINERGIC, DOPAMINERGIC AND ADRENERGIC ACTIVITY
  申请人：FARMITALIA CARLO ERBA S.r.l.

  公开号：EP0647222A1

  公开（公告）日：1995-04-12
• [EN] N(HETERO)-ARYL-N(HETERO)-TETRALIN-ALKYL-PIPERAZINE HAVING SEROTONINERGIC, DOPAMINERGIC AND ADRENERGIC ACTIVITY<br/>[FR] N(HETERO)-ARYL-N(HETERO)-TETRALIN-ALKYL-PIPERAZINE A ACTIVITE SEROTONINERGIQUE, DOPAMINERGIQUE ET ADRENERGIQUE
  申请人：FARMITALIA CARLO ERBA S.R.L.

  公开号：WO1994000441A1

  公开（公告）日：1994-01-06

  (EN) N(hetero)-aryl-N(hetero)-tetralinalkyl piperazine having serotoninergic, dopaminergic and adrenergic activity, the processes for their preparation and relative therapeutic compositions for the treatment of anxiety generated by depression, for the treatment of schizophrenia, cerebral ischemia, opium like and psycho stimulant substances abuse syndromes consciousness disorders such as senile dementia, vigilance and memory disorders. Parkinson's and Alzheimer's diseases and for the treatment of arterial hypertension.(FR) N(hétéro)-aryl-N(hétéro)-tétralin-alkyl-pipérazine à activité serotoninergique, dopaminergique et adrénergique, ses procédés de préparation, et compositions thérapeutiques associées destinées au traitement de l'angoisse provoquée par la dépression, au traitement de la schizophrénie, des accès ischémiques cérébraux, des syndromes dus à l'usage de substances psychostimulantes et opiacées, des troubles de la conscience tels que la démence sénile et les troubles de la vigilance et de la mémoire, et des maladies de Parkinson et d'Alzheimer, ainsi qu'au traitement de l'hypertension artérielle.